Enterprise Value
14.73M
Cash
18.32M
Avg Qtr Burn
-7.415M
Short % of Float
13.27%
Insider Ownership
8.86%
Institutional Own.
29.87%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TCR-T targeting neoantigens Details Solid tumor/s, Cancer | Phase 1/2 Update | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued |